Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2010-10-08 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
3 Filing
Director's Dealing
2010-10-08 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement regarding the sale of a combinatorial chemical library and associated technology. It includes details of the asset purchase agreement and references a press release dated October 7, 2010. There are no financial statements or detailed financial data presented, and the document primarily serves as an announcement of a transaction and related press release. This fits the category of Capital/Financing Update (CAP), as it relates to a significant transaction involving company assets and financial terms. The document length is 4659 characters, which is sufficient to contain substantive information rather than just a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2010-10-07 English
8-K Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes announcements about a licensing agreement and a novation agreement involving the company and other parties, along with a press release. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is relatively short (3864 characters) and primarily serves to disclose a material event rather than provide comprehensive financial or management information. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2010-09-17 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce major events or corporate changes that shareholders should know about. The content describes the termination of a material definitive agreement between Ligand Pharmaceuticals and GlaxoSmithKline. It does not contain financial statements or detailed financial performance data, nor is it an earnings release or annual/interim report. It is a regulatory announcement about a contract termination event. The document length is 3255 characters, which is relatively short and consistent with a regulatory filing rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2010-09-13 English
8-K Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 9, 2010, by Ligand Pharmaceuticals Incorporated. The content focuses on the submission of matters to a vote of security holders at a special meeting, specifically detailing the voting results on proposals related to a reverse stock split and adjournment to solicit additional proxies. This corresponds to an official announcement of voting results from a shareholder meeting. The document is relatively short (4269 characters) and contains detailed voting outcomes, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2010-09-10 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2010-08-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.